By practicing these precautions and maintaining open communication with your healthcare provider, you can ensure semaglutide is safe and suited to your needs
Its discouraging. In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight up to 50 pounds or more in many cases
Similar findings were replicated in the study population with T2D when comparing semaglutide with non-GLP-1RA anti-diabetes medications for incident CUD (HR: 0.40, 95% CI: 0.290.56) and recurrent CUD (HR: 0.66, 95% CI: 0.421.03)
For injection site reactions, patient education on proper injection technique is foundational
Viene somministrato una volta al giorno tramite iniezione sottocutanea
Cardiovascular Risk Reduction The SELECT trial showed semaglutide reduces the risk of major cardiovascular events (heart attack, stroke) by 20% in overweight or obese adults with established cardiovascular disease